Bracco Imaging has received approval from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) for the use of its MultiHance MRI agent for whole-body exams in both adults and children.
In addition to the U.K., the approval covers Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, the Netherlands, Norway, Spain, and Sweden, Bracco said.
The agent has already been approved in the European Union for use in MR exams of the central nervous system in children over 2 years of age and adults, as well as MR imaging of the liver and the breast, and MR angiography of renal and aortoiliofemoral occlusive diseases in adult patients, according to the firm.
